Group 1 - The company has reached a cooperation intention with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. regarding the self-developed BIOS-0629 project and signed a Technical Development Cooperation Agreement [1] - The company is responsible for the research and development, clinical trials, and registration application of the cooperative product [1] - Zhongshen Innovation is responsible for the R&D transformation, post-marketing production, sales, and market expansion in the Greater China region [1] Group 2 - Following the signing of the contract, Zhongshen Innovation will pay a milestone payment of 300 million yuan based on R&D milestones [1] - After the product is launched in the Greater China region, the company will receive a 10% commission on sales revenue [1]
百诚医药(301096.SZ)：BIOS-0629项目签署《技术开发合作协议》